Davis Polk Guides Roche In $8.4B Respiratory Drugmaker Buy
Swiss pharmaceutical giant Roche has agreed to buy California biotech InterMune for $8.4 billion cash in order to beef up its lineup of respiratory drugs, the companies announced Sunday, marking the...To view the full article, register now.
Already a subscriber? Click here to view full article